Medicine agency: Roche did not report side effects

June 22, 2012 by MARIA CHENG

(AP) — The European Medicines Agency is investigating "deficiencies" in the way drug maker Roche reported possible side effects in patients in the U.S., though it said there was no evidence patients are at risk.

European authorities spotted the problems during a routine inspection of Roche by British regulators in May. They noticed about 80,000 reports of possible side effects for medicines sold in the U.S. had not been analyzed to see if they were truly suspected adverse effects that needed to be reported. The reports were collected in a patient program that helps people deal with health insurance issues in the U.S., like reimbursement for medicines. Dozens of drugs were involved, including many cancer drugs.

In the reports of possible side effects, there were more than 15,000 deaths. The European Medicines Agency said it was unclear whether those deaths were linked to any Roche medicines.

"The scale of it sounds big, but what is not known is how many of these deaths have already been reported in another way," said Monika Benstetter, an EMA spokeswoman. "We need to get to the bottom of this."

Drug agencies regularly track side effects of drugs on the market since rare adverse events might not have been picked up during clinical trials when only limited numbers of people are exposed to the medicines.

Roche AG acknowledged it did not fully comply with regulations on the reporting system and that it was working "to address this matter expeditiously." Possible side effects picked up by the patient support program were not sent to Roche's own database for evaluation and therefore never made it to health officials, according to spokesman Daniel Grotzky. He said both minor and serious side effects were reported but could not provide further details.

"This was not intentional but of course it's not something that should have happened," Grotzky said. "We're looking into all of these cases and we will work with health authorities to update them." He said preliminary numbers had been given to health authorities about the potential number of missed adverse events and that measures would be taken to update their database. Grotzky said they hoped to have final numbers by January.

The EMA has given Roche until Wednesday to submit a detailed plan on how they will evaluate and report all outstanding cases, including how such problems will be corrected in the future.

"Based on the information we have, there is no need for patients to change their treatment," Benstetter said. "But we need more evidence that these deficiencies are being addressed."

Explore further: Roche probed over faulty drug-safety reporting

shares

Related Stories

Roche probed over faulty drug-safety reporting

June 21, 2012
Swiss pharmaceutical giant Roche is under investigation over a failure to properly report adverse drug side-effects, the European Medicines Agency (EMA) said on Thursday.

Effects of Tamiflu still uncertain, warn experts, as Roche continues to withhold key trial data

January 18, 2012
Two years after pharmaceutical giant Roche promised the BMJ it would release key Tamiflu trial data for independent scrutiny, the safety and effectiveness of this anti-influenza drug remains uncertain, warn experts today.

Roche extends its hostile takeover bid for Illumina

February 27, 2012
Swiss pharmaceutical group Roche said Monday it is sticking by its hostile $5.7-billion (4.2 billion euros) bid for US gene mapper Illumina and is extending it for a month.

Novartis drug investigated after 11 deaths

January 20, 2012
A multiple sclerosis drug made by industry giant Novartis is under investigation after at least 11 patients taking the medicine died.

US revokes Roche's Avastin for breast cancer

November 18, 2011
US health officials on Friday revoked the authorization of Roche's Avastin for breast cancer treatment, saying it concluded the drug had "not been shown to be safe and effective for that use."

Recommended for you

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

At-risk chronic pain patients taper opioids successfully with psychological tools

June 28, 2017
Psychological support and new coping skills are helping patients at high risk of developing chronic pain and long-term, high-dose opioid use taper their opioids and rebuild their lives with activities that are meaningful ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.